
120
100
80
60
40
20
0
Incidence of safety events (%)
HLX02 (n = 37)
US-trastuzumab (n = 37)
EU-trastuzumab (n = 37)
TEAEs
CTCAE Grade ≥3 TEAEs
ADRs
SAEs